Company Overview
Company Name
Arcellx
Address
United States
Website
arcellx.comApprox. Annual Revenue
$0.4M
Employees
6
Established
2015
About Arcellx
Arcellx is a United States-based company focused on developing cell therapies for the treatment of cancer and autoimmune diseases. The company's technology platforms, including the D-Domain and DDCAR technologies, aim to reimagine and supercharge cell therapy approaches to cancer treatment. Arcellx is driven by a mission-critical collaboration and an empathetic team, dedicated to transforming the fight against cancer.
Business Profile
Read from the Arcellx website on Oct 14, 2026. Hover an item to see the exact wording it came from.
About the website
- Website quality (AI-assessed)
- 8/10 · Current news and press releases; Detailed patient and pipeline information
- Footer copyright year
- 2026
Announcements
As stated on the Arcellx website.
- New ownership“Gilead Sciences Completes Acquisition of Arcellx”
Recent changes
What changed on the Arcellx website and Google listing, as detected by Coldlytics on each visit.
New ownership announced
Gilead Sciences Completes Acquisition of Arcellx
LinkedIn Insight tag installed
Google Ads pixel installed
Meta (Facebook) ad pixel installed
Coldlytics tracks changes like these across millions of businesses, so you can reach companies the moment they add a pixel, start hiring, or switch software.
Find companies by what just changed →Biotech & Life Sciences Companies near DC
- Biogenhibio.com
- Mid-Atlantic Bio Angelsbioangels.net
- Octapharmaoctapharmausa.com
- Galectin Therapeuticsgalectintherapeutics.com
- Likardalikarda.com
- Otolith Labsotolithlabs.com
- United Therapeuticslungbiotechnology.com
- CCS Associatesccsainc.co
- Avaniaavaniaclinical.com
- Emerson Clinical Research Instituteecrinstitute.com
Frequently Asked Questions about Arcellx
Advertising Pixels
- Facebook Ad Pixel
- Google Ad Pixel
- LinkedIn Ad Pixel
Categories
Technologies Used
'%20fill='%23CE1312'%3e%3cpath%20d='M219.044,391.269916%20L219.0425,377.687742%20L232.0115,384.502244%20L219.044,391.269916%20Z%20M247.52,375.334163%20C247.52,375.334163%20247.0505,372.003199%20245.612,370.536366%20C243.7865,368.610299%20241.7405,368.601235%20240.803,368.489448%20C234.086,368%20224.0105,368%20224.0105,368%20L223.9895,368%20C223.9895,368%20213.914,368%20207.197,368.489448%20C206.258,368.601235%20204.2135,368.610299%20202.3865,370.536366%20C200.948,372.003199%20200.48,375.334163%20200.48,375.334163%20C200.48,375.334163%20200,379.246723%20200,383.157773%20L200,386.82561%20C200,390.73817%20200.48,394.64922%20200.48,394.64922%20C200.48,394.64922%20200.948,397.980184%20202.3865,399.447016%20C204.2135,401.373084%20206.612,401.312658%20207.68,401.513574%20C211.52,401.885191%20224,402%20224,402%20C224,402%20234.086,401.984894%20240.803,401.495446%20C241.7405,401.382148%20243.7865,401.373084%20245.612,399.447016%20C247.0505,397.980184%20247.52,394.64922%20247.52,394.64922%20C247.52,394.64922%20248,390.73817%20248,386.82561%20L248,383.157773%20C248,379.246723%20247.52,375.334163%20247.52,375.334163%20L247.52,375.334163%20Z'%20id='Youtube'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
%20--%3e%3csvg%20version='1.1'%20id='st_x5F_cc_x5F_app_x5F_RGB.svg'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20240.0004%20234.0004'%20style='enable-background:new%200%200%20240.0004%20234.0004;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:url(%23SVGID_1_);}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3clinearGradient%20id='SVGID_1_'%20gradientUnits='userSpaceOnUse'%20x1='119.9997'%20y1='234.0002'%20x2='119.9997'%20y2='0.0002'%3e%3cstop%20offset='0'%20style='stop-color:%23201F21'/%3e%3cstop%20offset='1'%20style='stop-color:%23313131'/%3e%3c/linearGradient%3e%3crect%20x='-0.0003'%20y='0.0002'%20class='st0'%20width='240'%20height='234'/%3e%3cg%3e%3cpath%20class='st1'%20d='M132.24969,97.95853c-5.60328,18.77988-10.28088,36.91208-15.88416,54.63138%20c-3.18081,9.99579-6.66385,19.53729-11.05544,25.59485c-4.84678,6.81497-13.93402,13.32771-24.83743,13.32771%20c-7.72443,0-15.29683-3.63509-15.29683-11.66174c0-4.99789,5.14901-9.69264,9.23837-9.69264%20c2.42339,0,3.63508,1.36282,4.24046,2.42339c3.7862,6.81497,7.42128,10.75229,9.08724,10.75229s3.02878-2.27135,5.7544-12.1151%20l19.82331-73.26013H99.08337c-1.06058-3.18081,0.45427-7.11812,2.27135-7.87554h14.23625%20c2.72562-8.7841,5.92356-17.60862,10.46719-25.63529c6.81497-12.26713,17.7193-21.95976,32.71205-21.95976%20c11.3586,0,16.05333,5.45216,16.05333,12.41917c-0.15111,7.42036-6.66293,11.20656-9.69263,11.20656%20c-2.42247,0-3.63416-1.81709-4.39159-4.39159c-2.57451-9.69263-5.90643-12.57029-7.87555-12.57029%20c-1.9682,0-4.99789,3.63416-8.3289,11.20656c-4.3925,9.54151-7.28729,19.72977-10.01291,29.72464h17.26501%20c1.05966,2.12023,0.15112,6.66385-2.42339,7.87554H132.24969z'/%3e%3c/g%3e%3c/svg%3e)
Key Decision Makers
Emily Pearson Clinical Trial Manager